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Yoshihiro Inamoto,1 Paul J. Martin,1 Xiaoyu Chai,1 Madan Jagasia,2 Jeanne Palmer,3
Joseph Pidala,4 Corey Cutler,5 Steven Z. Pavletic,6 Mukta Arora,7 David Jacobsohn,8
Paul A. Carpenter,1 Mary E. D. Flowers,1 Nandita Khera,1 Georgia B. Vogelsang,9
Daniel Weisdorf,7 Barry E. Storer,1 Stephanie J. Lee,1 on behalf of the
Chronic GVHD ConsortiumTo determine whether changes in objective response measures proposed by theNational Institutes of Health
correlate with clinical benefit, such as symptom burden, quality of life, and survival outcomes, we analyzed
data from a multicenter prospective cohort of 283 patients with chronic graft-versus-host disease requiring
systemic treatment. The median follow-up time of survivors was 25.1 months (range, 5.4-47.7 months) after
enrollment. Symptom measures included the Lee symptom scale and 10-point patient-reported symptoms.
Quality-of-life measures included the Short Form-36, Functional Assessment of Cancer Therapy–Bone Mar-
row Transplantation, and Human Activities Profile. Overall and organ-specific responses were calculated by
comparing manifestations at the 6-month visit and those at the enrollment visit using a provisional algorithm.
Complete or partial responses were considered ‘‘response,’’ and stable or progressive disease was consid-
ered ‘‘no response.’’ Overall response rate at 6 months was 32%.Organ-specific response rates were 45% for
skin, 23% for eyes, 32% for mouth, and 51% for gastrointestinal tract. Response at 6 months, as calculated
according to the provisional response algorithm, was correlated with changes in symptom burden in patients
with newly diagnosed chronic graft-versus-host disease, but not with changes in quality of life or survival out-
comes. Modification of the algorithm or validation of other more meaningful clinical endpoints is warranted
for future clinical trials of treatment for chronic graft-versus-host disease.
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Chronic graft-versus-host disease (GVHD) is one
of the most devastating long-term complications after
allogeneic hematopoietic cell transplantation [1].
Clinical treatment decisions are generally based on
physician-assessed response, and the degree of
physician-assessed response has served as the primary end-
point in clinical trials [2]. The definitions of physician-
assessed response used in previous studies have often
been vague and subjective, however. The lack of stan-
dardized quantitative response criteria has been one of
the major obstacles in the field [3].
In 2005, the National Institutes of Health (NIH)
Consensus Conference recommended measurement
tools to capture clinician and patient-assessed chronic
GVHDmanifestations [4]. TheNIHConsensusConfe-
rence also recommended a set of provisional algorithms
to calculate overall and organ-specific responses using
these objective response measures [5]. The algorithms
were based on expert opinions, with the recognition
that they needed to be validated and refined according1517
Table 1. Proposed Provisional Algorithms for Calculation of
Organ Response
Response Organ and Starting Score or Value Criterion
CR Skin, % of body surface area 0
Eyes, NIH severity score Score 0
Mouth, 15-point Schubert scale Score 0
GI, NIH severity score Score 0
Liver function tests
(ALT, ALP, bilirubin)
#ULN
PR Skin, % of body surface
>50 e/s # 0.5; e > 0
25-50 s 2 e $ 25; e > 0
<25 only CR; no PR possible
Eyes and GI, NIH severity score
3 e 1 or 2
1518 Biol Blood Marrow Transplant 18:1517-1524, 2012Y. Inamoto et al.to data emerging from prospective studies. TheChronic
GVHDConsortium was established to collect prospec-
tive observational data for this purpose [6].
In the present study, we analyzed the correlations
of the calculated response based on the provisional al-
gorithm with symptom burden, quality-of-life (QOL),
and survival outcomes. We chose these endpoints as
gold standards for our analysis because they represent
clinical benefit, or ‘‘living better or living longer’’ as
defined by the US Food and Drug Administration
[7-9]. If the calculated response is to be used as an
endpoint in clinical trials, it should correlate with
these well-recognized measures of clinical benefit.2 e 1
1 only CR; no PR possible
Mouth, 15-point Schubert scale
>8 e/s # 0.5 and e > 0
4-7 s 2 e $ 4 and e > 0
<4 only CR; no PR possible
Liver function tests
(ALT, ALP, bilirubin)
$3 times ULN e/s # 0.5 and e > ULN
<3 times ULN only CR; no PR possible
PD Skin, % of body surface e 2 s $ 25
Eyes and GI, NIH severity score e 2 s $ 1
Mouth, 15-point Schubert scale e 2 s $ 3
Liver function tests
(ALT, ALP, bilirubin)
s $3 times ULN e 2 s $ 3 times ULN
s <3 times ULN e 2 s $ 2 times ULN
Lungs, 12-point lung function scale e 2 s $ 3*
SD Any organ None of the above
ALP indicates alkaline phosphatase; ALT, alanine transaminase; e, ending
score or value; s, starting baseline score or value; ULN, upper limit of
normal.
*If the starting lung function score was$10, progression was defined as
a$5% decrease in forced expiratory volume in 1 second in 2 measure-
ments made at least 2 weeks apart. This time interval was selected
because these syndromes can progress rapidly.PATIENTS AND METHODS
Study Cohort
We studied 283 patients with chronic GVHDwho
received systemic treatment andwere enrolled in amul-
ticenter, prospective, longitudinal, observational co-
hort study between August 2007 and December 2010
(registered as NCT00637689) and had a 6-month visit
after enrollment [6]. In all patients, the diagnosis of
chronic GVHD was made according to the NIH con-
sensus criteria [10]. Patients at least 2 years of age who
received systemic treatment for chronic GVHD were
eligible for enrollment. Newly diagnosed, incident
cases were defined as enrollment within 3 months after
diagnosis of chronic GVHD, and prevalent cases were
defined as enrollment 3 or more months after diagnosis
but within 3 years after transplantation. Patients were
evaluated at the transplantation center every 6 months,
and those with incident GVHD underwent an addi-
tional assessment at 3 months after enrollment. Treat-
ment of chronic GVHD was not uniform or
mandated for this study, although compliance with
the NIH consensus guidelines for chronic GVHD
was encouraged [11]. The study protocol was approved
by the Institutional Review Board of each participating
center, and all participants or their guardians gave writ-
ten informed consent.
Response Calculation
Organ involvement at the enrollment visit was de-
fined as a NIH organ score of 1 or greater. Lung in-
volvement was based on pulmonary function tests if
available or on lung symptom scores otherwise. Re-
sponses were calculated according to the provisional
response algorithm [4,5,12] as complete response
(CR), partial response (PR), stable disease (SD), or
progressive disease (PD) separately in the skin, eyes,
mouth, gastrointestinal (GI) tract, liver, and lung, as
well as overall (Table 1). The algorithm compares or-
gan manifestations reported at the 6-month follow-up
visit and those reported at the enrollment visit. Note
that the NIH eye score was used instead of Schirmer’stest to calculate response in the eye [12]. CR in an or-
gan indicates resolution of all reversible manifestations
related to chronic GVHD, PR indicates at least 50%
improvement, PD indicates an absolute increase of at
least 25% or a new organ involvement, and SD indi-
cates none of the above.
Overall response was calculated as follows. Overall
CR was defined as attainment of CR in all involved or-
gans with no evidence of PD in any organ, overall PR
was defined as the presence of PR in at least one in-
volved organ without evidence of PD in any organ,
overall PDwas defined as the presence of PD in any or-
gan or any new organ involvement, and overall SD was
defined as none of the above. For consistency with
most published phase II studies [13-16], CR or PR
was considered ‘‘response,’’ whereas SD or PD was
considered ‘‘no response’’ at the 6-month time point.
Patient-Reported Outcomes
Symptom measures included the Lee symptom
scale and 10-point patient-reported global rating of
symptoms [17,18]. QOL and functional measures
Biol Blood Marrow Transplant 18:1517-1524, 2012 1519Response Criteria for Chronic GVHD and Clinical Benefitincluded the Short Form-36 (SF-36), Functional
Assessment of Cancer Therapy–Bone Marrow
Transplantation (FACT-BMT), and Human Activities
Profile (HAP) [19-21]. All of these instruments have
been recommended by the NIH Consensus
Conference as patient-reported measures for chronic
GVHD [4]. The Lee symptom scale is a 30-item patient
self-administered questionnaire specific to symptoms of
chronic GVHD in the skin, eyes, mouth, respiratory
system, andmuscles and joints, alongwith nutrition, en-
ergy, andmental and emotional aspects [17]. Symptoms
related tonutritionwere consideredGI symptoms in the
present analysis. Patients also reported the severity of
skin itching, mouth dryness, mouth pain, mouth sensi-
tivity, eye problems, and overall chronic GVHD sever-
ity on a 10-point scale for peak severity during the
previousweek, as recommended by theNIHConsensus
Conference [18].
The SF-36, version 2 is a 36-item self-reported
questionnaire that assesses patient-reported health
and functioning [19]. Two summary scales from the
SF-36 include the physical component score (PCS)
and the mental component score (MCS). The
FACT-BMT, version 4.0 is a 37-item self-reported
questionnaire that includes a 10-item bone marrow
transplantation subscale [20]. The HAP is a 94-item
self-reported assessment of energy expenditure or
physical fitness that was originally developed in a pop-
ulation of patients with pulmonary disease and has
been validated in patients with chronic GVHD [21].
Statistical Analysis
Patient characteristics are presented as median and
range for continuous variables and as frequency and
percentage for categorical variables. Multivariate lin-
ear regression models were used to estimate the corre-
lation of the calculated overall and organ-specific
response at the 6-month visit with a change in symp-
tom or QOL measures from baseline in patients who
completed the pertinent questionnaire and demon-
strated involvement at baseline. Patient characteristics
used for adjustment in all models included case type
(incident versus prevalent), donor–recipient sex match,
stem cell source, donor–recipient cytomegalovirus sta-
tus, and NIH global severity score at enrollment. Sta-
tistical interactions between explanatory variables and
adjusted patients characteristics were tested.
A second analysis was designed to determine
whether changes in patient-reported outcomes were
clinically meaningful, as defined by the NIH Consen-
sus Conference or previously published criteria. In
brief, a 2-point change on a 10-point scale was consid-
ered clinically meaningful for global rating of symp-
toms [4,22], whereas a 0.5-standard deviation change
was used for the others [4,23,24]. Agreement
between the NIH response and clinically meaningful
improvement in each measure was examined usingthe k statistic. Empirical interpretation was used for
k coefficients (0, no agreement; 0-0.2, slight
agreement; 0.2-0.4, fair agreement; 0.4-0.6, moderate
agreement; 0.6-0.8, substantial agreement; and
0.8-1.0, almost perfect agreement).
Overall survival (OS) was calculated from the date
of the 6-month visit to the date of death or last follow-
up using the Kaplan-Meier method. Nonrelapse mor-
tality (NRM) was defined as any death without relapse,
and the cumulative incidence of NRM was estimated
with relapse considered a competing risk [25]. Land-
mark analyses fitting Cox regression models were
used to compare overall mortality and NRM from
the 6-month visit according to the NIH overall
response at that time. Hazard ratios (HRs) were esti-
mated with adjustment for known risk factors, includ-
ing months from transplantation to enrollment in the
cohort, platelet count at onset of chronic GVHD,Kar-
nofsky performance status at onset of chronic GVHD,
patient age at transplantation, donor and HLA match-
ing, donor–recipient sex match, previous grade II-IV
acute GVHD, andNIH global severity score at enroll-
ment. Statistical analyses were performed with SAS/
STAT software, version 9.2 (SAS Institute, Cary,
NC) and R version 2.9.2 (R Foundation for Statistical
Computing, Vienna, Austria).RESULTS
Patient Characteristics
The median patient age at enrollment was 51 years
(range, 2-79 years), the median time from transplanta-
tion to enrollment was 12.2 months (range, 2.9-38.5
months), and the median time from onset of chronic
GVHD to enrollment was 2.5 months (range, 0-31.5
months). Of the 283 patients, 150 (53%) were incident
cases, 252 (89%) underwent mobilized blood cell
transplantation, 133 (47%) had an HLA-matched
related donor, 107 (38%) had an HLA-matched unre-
lated donor, 153 (54%) received myeloablative condi-
tioning, and 151 (53%) had previous grade II-IV acute
GVHD. The organs most frequently involved at en-
rollment were the mouth (61%) and skin (60%). Of
the 138 cases with lung involvement, 113 (82%) were
based on pulmonary function tests, and 25 (18%)
were based on lung symptom score. Eighty patients
(28%) had severe NIH global severity at enrollment.
Other demographic characteristics of patients are
summarized in Table 2.
Patient-Reported Outcomes According to
Response
The calculated overall response was not available
for 3 patients (1%). As shown in Figure 1, 12 patients
(4%) had overall CR, 77 (28%) had overall PR, 15
(5%) had overall SD, and 176 (63%) had overall PD,
Table 2. Patient Characteristics (n 5 283)
Characteristic Value
Age at enrollment, years
Median 51
Range 2-79
Sex, n (%)
Male 166 (59)
Female 117 (41)
Time from transplantation to enrollment, months
Median 12.2
Range 2.9-38.5
Type of case, n (%)
Incident 150 (53)
Prevalent 133 (47)
Disease stage, n (%)*
Early 98 (35)
Intermediate 125 (44)
Advanced 60 (21)
Graft source, n (%)
Bone marrow 18 (6)
G-CSF–mobilized peripheral blood 252 (89)
Cord blood 13 (5)
Donor and HLA matching, n (%)
HLA-matched related 133 (47)
HLA-matched unrelated 107 (38)
HLA-mismatched related or unrelated 43 (15)
Conditioning regimen
Myeloablative 153 (54)
Nonmyeloablative/reduced-intensity 130 (46)
Donor–recipient sex match, n (%)
Female to male 80 (28)
Other 200 (71)
Unknown 3 (1)
Donor–recipient cytomegalovirus status, n (%)
Either positive 189 (66)
Both negative 93 (33)
Unknown 1 (1)
Previous grade II-IV acute GVHD, n (%)
Present 151 (53)
Absent 132 (47)
Chronic GVHD organ involvement at enrollment, n (%)
Skin 171 (60)
Eyes 135 (48)
Mouth 173 (61)
GI tract 80 (28)
Liver† 142 (51)
Lung 138 (49)
Joints or fascia 82 (29)
Genital tract‡ 24 (10)
Subcategory of chronic GVHD at enrollment, n (%)
Classic chronic GVHD 49 (17)
Overlap syndrome 234 (83)
Platelet count at onset, n (%)
<100,000/mL 56 (20)
$100,000/mL 222 (78)
Not available 5 (2)
Total serum bilirubin at onset, n (%)
>2 mg/dL 12 (4)
#2 mg/dL 262 (93)
Not available 9 (3)
NIH global severity at enrollment, n (%)
Mild 36 (13)
Moderate 167 (59)
Severe 80 (28)
Type of systemic treatment at enrollment, n (%)
Prednisone plus calcineurin inhibitor 130 (46)
Prednisone alone 62 (22)
Calcineurin inhibitor alone 50 (18)
Others 41 (14)
*Early disease includes acute leukemia in first remission, chronic myelog-
enous leukemia in chronic phase, myelodysplastic syndromewithout ex-
cess blasts, and nonmalignant diseases. Advanced disease includes acute
leukemia in third or later remission, malignant disease not in remission,
Figure 1. Calculated response overall and in individual organs at 6
months after enrollment, according to the provisional algorithm.
1520 Biol Blood Marrow Transplant 18:1517-1524, 2012Y. Inamoto et al.for an overall response rate of 32% at 6 months.
Organ-specific response rates at 6 months were 45%
for skin, 23% for eyes, 32% for mouth, 51% for GI
tract, and 54% for liver. Compliance rates of the symp-
tom and QOL measures ranged from 83% to 89% at
enrollment and from 77% to 83% at 6 months. Pa-
tients who did not complete the measures were not in-
cluded in the correlation analyses. Baseline values for
symptom and QOL measures were similar in incident
cases and prevalent cases (P values5 .10-.64). Correla-
tions of calculated overall response with changes in
symptom and QOL measures are shown in Table 3.
Given the different patterns in the incident and preva-
lent cases, an interaction effect between the NIH re-
sponse and case type was added to each model.
Among incident cases, overall responders had im-
proved overall symptom measures compared with
nonresponders; for example, the estimated change in
the Lee symptom overall score over 6 months after en-
rollment was 7.8 points lower (ie, better) in responders
than in nonresponders. Overall response was not asso-
ciated with changes in symptom measures in prevalent
cases, however. No association was observed between
overall response and QOL measures in either incident
or prevalent cases. Type of systemic treatment at en-
rollment was not associated with subsequent changes
in symptom or QOL measures (P 5 .28-.99).and chronic myelogenous leukemia in blast crisis. All other diseases and
stages are categorized as intermediate risk.
†Data not available for 2 patients.
‡Data not available for 32 patients.
Table 3. Correlation of Calculated Overall Response with Changes in Symptom and QOL Measures
Outcome
Clinically Meaningful
Change*
Incident Cases Prevalent Cases
Estimated Difference† 95% CI P Value Estimated Difference† 95% CI P Value
Symptom measure
Lee symptom overall score 6.1 27.8 212 to 24.1 <.001 21.8 25.5 to 1.8 .33
10-point patient-rated
overall symptoms
2 21.5 22.4 to 20.6 .001 20.5 21.3 to 0.4 .32
QOL measure
SF-36 PCS 4.8 0.9 22.7 to 4.5 .62 1.2 22.4 to 4.8 .52
SF-36 MCS 5.2 0.9 22.9 to 4.8 .64 0.1 23.8 to 4.0 .95
FACT-BMT 9.9 5.4 20.8 to 12 .09 2.3 24.1 to 8.7 .48
HAP-MAS 6.3 4.0 21.4 to 9.3 .14 21.9 27.3 to 3.6 .50
HAP-AAS 8.3 3.5 22.3 to 9.4 .24 1.0 24.9 to 6.9 .74
AAS indicates adjusted activity score; MAS, maximum activity score.
*A 0.5 standard deviation in baseline score or 2-point change on a 10-point scale.
†Adjusted estimated difference between changes experienced by responders compared with nonresponders. For example, among incident cases, the
change in the Lee symptom overall score over 6 months after enrollment was an estimated 7.8 points lower (ie, better) in responders than in nonre-
sponders. Results are derived from one model.
Biol Blood Marrow Transplant 18:1517-1524, 2012 1521Response Criteria for Chronic GVHD and Clinical BenefitWe next analyzed symptom and QOL measures at
6 months according to treatment type at 6 months.
Prednisone treatment at 6 months was associated
with higher overall symptom burden by both the Lee
symptom overall score (P 5 .016) and 10-point
patient-reported overall symptoms (P 5 .0043) and
with worse QOL by the SF-36 MCS (P 5 .022) and
FACT-BMT (P5 .0019). Treatment with daily pred-
nisone as compared to alternative day or less frequent
administration at 6 months was associated with higher
overall symptom burden by both the Lee symptom
overall score (P 5 .039) and 10-point overall symp-
toms (P 5 .022), with worse QOL by the SF-36 PCS
(P 5 .0017) and FACT-BMT (P 5 .0091) and with
worse HAP maximum activity score (P 5 .005) and
HAP-adjusted activity score (P 5 .0013). Treatment
with a calcineurin inhibitor at 6 months was not asso-
ciated with symptom or QOL measures.
Correlations of calculated organ response with
changes in symptom measures for individual organs
are shown in Table 4. Among incident cases, organ re-Table 4. Correlation of Calculated Organ Response with Change in
Outcome Clinically Meaningful Change*
Incident
Estimated Difference†
Lee symptom scale
Skin 10.2 29.9 2
Eyes 14.8 228 2
Mouth 14.0 219 2
GI (nutrition) 6.3 212 2
10-point patient-rated
symptoms
Skin itching 2 22.1 2
Eye problem 2 22.3 2
Mouth dryness 2 0.02 2
Mouth pain 2 20.9 2
Mouth sensitivity 2 20.9 2
*A 0.5 standard deviation in baseline score or a 2-point change on a 10-point
†Adjusted estimated difference between changes experienced by responders
change in the Lee symptom skin score over 6 months after enrollment was a
sponders. Results are derived from one model.sponse was associated with improved symptom mea-
sures for the skin, eyes, mouth, and GI tract by the
Lee symptom scale and with improved symptom mea-
sures for the skin and eyes by the 10-point symptom
scale. Among prevalent cases, organ response was asso-
ciated with improved symptom measures in the
10-point mouth pain and sensitivity but not with
changes in the 10-point skin itching, eye problem, or
mouth dryness or in the Lee symptom scales.
We also examined agreement between the calcu-
lated response and clinically meaningful improvement
in symptoms or QOL measures among incident cases
(Table 5). The calculated response rates ranged from
20% to 54%, and the rates of clinically meaningful im-
provement ranged from 20% to 41%. Although these
rates appeared similar, k statistics showed no better
than fair agreement between the calculated response
and clinicallymeaningful improvement for allmeasures
(k520.04 to 0.39). Agreement for symptommeasures
(k 5 0.09-0.39) appeared to be better than agreement
for QOL measures (k5 20.04 to 0.14).Symptom Measures for Individual Organs
Cases Prevalent Cases
95% CI P Value Estimated Difference† 95% CI P Value
18 to 21.4 .02 24.0 214 to 6.2 .44
44 to 212 <.001 29.0 222 to 4.5 .19
30 to 27.6 .001 211 223 to 0.7 .07
20 to 24.3 .003 21.7 210 to 6.9 .69
3.2 to 21.0 <.001 0.6 20.7 to 1.8 .39
4.0 to 20.6 .009 20.7 22.1 to 0.8 .37
1.3 to 1.3 .98 20.8 22.1 to 0.6 .26
2.1 to 0.3 .13 21.3 22.6 to 20.1 .03
2.1 to 0.3 .16 21.3 22.6 to 20.04 .04
scale.
compared with nonresponders; for example, among incident cases, the
n estimated 9.9 points lower (ie, better) in responders than in nonre-
Table 5. Agreement between Response and Clinically
Meaningful Improvement in Each Measure among Incident
Cases
Outcome
NIH
Response
Clinically Meaningful
Improvement k Value
Symptom measure
Lee symptom scale
Overall 32% 30% 0.30
Skin 54% 41% 0.32
Eyes 20% 22% 0.32
Mouth 33% 36% 0.31
GI (nutrition) 53% 40% 0.39
Ten-point patient-rated
symptoms
Overall 32% 31% 0.20
Skin itching 54% 28% 0.27
Eye problem 20% 20% 0.19
Mouth dryness 33% 37% 0.09
Mouth pain 33% 38% 0.32
Mouth sensitivity 33% 29% 0.12
QOL measure
SF-36 PCS 32% 32% 20.04
SF-36 MCS 32% 24% 20.02
FACT-BMT 32% 26% 0.13
HAP MAS 32% 36% 0.11
HAP AAS 32% 36% 0.14
AAS indicates adjusted activity score; MAS, maximum activity score.
Figure 2. Survival outcomes according to overall response at 6
months. (A) OS. (B) NRM. P values are derived from the adjusted
Cox model.
1522 Biol Blood Marrow Transplant 18:1517-1524, 2012Y. Inamoto et al.Survival Outcomes According to Response
The median follow-up time of survivors was 25.1
months (range, 5.4-47.7 months) after enrollment.
Figure 2 displays OS andNRM from the 6-month visit
according to the calculated overall response at that
time. After adjusting for known chronic GVHD risk
factors, overall responders exhibited no statistically
significant difference in the risk of overall mortality
(adjusted HR, 0.6; 95% confidence interval [CI],
0.2-1.4; P 5 .20) or NRM (adjusted HR, 0.8; 95%
CI, 0.3-2.2; P 5 .69) compared with nonresponders.
Results were similar when analyses were separated by
incident cases versus prevalent cases, and no significant
statistical interaction was noted between overall re-
sponse and case type for overall mortality and NRM.
Type of systemic treatment at enrollment was not as-
sociated with subsequent overall mortality (P 5 .29)
or NRM (P 5 .38).
DISCUSSION
The calculated overall and organ-specific re-
sponses at 6 months correlated with the corresponding
overall and organ-specific changes in patient-reported
symptom burden among incident cases. However, the
calculated overall response at 6 months did not corre-
late with changes in QOL measures or with survival
outcomes.
Symptom burden is very important in patients with
chronic GVHD and is of great interest in clinical trials
as a secondary endpoint [2]. The results of our multi-
variate analyses suggest that the calculated response
is correlated with a change in patient symptom burden
among incident cases but not among prevalent cases.Thus, according to the current provisional algorithm
for calculating response, patients enrolled in clinical
trials more than 3 months after being diagnosed with
chronic GVHD might not exhibit a detectable change
in patient-reported outcomes even if chronic GVHD
were to improve.We hypothesize that this discrepancy
might be related to the fact that symptoms are more
amenable to treatment early after diagnosis, or that
changes in symptoms are less readily perceptible in
patients with long-established chronic GVHD.
Patient-reported QOL captures patients’ percep-
tions of their functional ability and well-being.
Improvements in these measures are considered a clin-
ical benefit, fulfilling one component for regulatory
approval [7,8]. Our analysis found no correlation
between patients with responses at 6 months and
changes in QOL. Another study from our
Consortium reported a poor correlation between
changes in NIH global severity scores and changes in
Biol Blood Marrow Transplant 18:1517-1524, 2012 1523Response Criteria for Chronic GVHD and Clinical BenefitQOL measures for chronic GVHD [26]. The lack of
correlation between calculated responses and QOL
might stem from the fact that the 2 measures reflect
fundamentally different aspects of GVHD or have dif-
fering sensitivity to changes [27]. Alternatively, resolu-
tion of chronic GVHD might not readily produce
a detectable change in QOL measures, given that
QOL is affected by many factors other than chronic
GVHD, including toxicities of previous treatments
for the underlying disease, immunosuppressive treat-
ment, and fixed deficits caused by chronic GVHD. Al-
though steroid dose and frequency of administration
were associated with symptom and QOL measures at
6 months, our data cannot distinguish cause from ef-
fect; for example, prednisone treatment and dosing
may reflect a high symptom burden, or prednisone
treatment could be causing more symptoms.
Whether or not complete resolution of chronic
GVHD activity results in significant improvement in
QOL measures remains controversial [28]. A previous
retrospective study found that patients who experi-
enced chronic GVHD had persistently worse QOL
than those who never had chronic GVHD at more
than 10 years after transplantation, even though half
of the patients had resolved chronic GVHD by that
time [29]. Another large prospective observational
study using patient-reported activity of GVHD found
better QOL in patients with resolved chronic GVHD
compared with patients with active chronic GVHD
[30]. However, the foregoing studies included patients
at least 2 years posttransplantation, whereas themedian
time from transplantation to enrollment in our cohort
was 12 months, perhaps too soon to observe an im-
provement in QOL measures. Another caveat is that
the previous studies used different QOL measures
with perhaps differing sensitivities to responses. The
source of information about chronic GVHD may be
important as well; previous studies have shown that
changes in patient-reported severity of chronic
GVHDwere associatedwith changes inQOL,whereas
changes in physician-assessed severitywere not [26,30].
The choice of assessment time points might affect
the ability to detect a correlation between chronic
GVHD response and outcomes. We chose a 6-month
time point for the present study, because it has been
the most commonly used time point in clinical studies
to date [13-16] and because improvement in some
manifestations of chronic GVHD, such as skin
sclerosis, may not be apparent until after 3 months
posttransplantation [31]. Chronic GVHD is a chronic
illness requiring systemic immunosuppressive treat-
ment for amediandurationof 2 to 3 years to achieve tol-
erance [32]. A previous study showed that short-term
response was not able to predict long-term treatment
success, defined as withdrawal of all immunosuppres-
sive treatmentwithout secondary systemic treatment af-
ter initial systemic treatment of chronic GVHD [33].Assessment of response at a later time point might pro-
vide better associations with QOL or survival, because
more patients may withdraw from immunosuppressive
treatment by then, and thusQOLmay improvewithout
the side effects of medications. The inclusion of more
patients and use of longer follow-up times may reveal
survival differences, although the current cohort was
large, and the median survival was 25.1 months.
The current algorithm for calculating response is
provisional and has several limitations. First, distinc-
tions between reversible disease activity and irrevers-
ible damage are not clear, especially for some fibrotic
manifestations, such as contractures, bronchiolitis ob-
literans, and sicca syndrome, where responses are dif-
ficult to achieve [2]. Second, objective response
measures for joints and the urogenital tract were not
addressed by the NIH Consensus Conference. Third,
the optimal cutoff points and measures were based on
consensus and should be refined now that data are
available [12,34-37]. Finally, the proportion of
overall CR was very low at 6 months, precluding
analyses focused solely on patients with CR.
In the present study, we did not evaluate responses
to specific drugs but rather correlated different possi-
ble measures of response. This is an important distinc-
tion, because the duration of response and fluctuating
disease activity did not affect our results. We were
looking for internal consistency in the various mea-
sures that we collected at 2 different time points, re-
gardless of why the patient’s condition improved or
worsened. We would still hope to measure improve-
ments with our instruments in patients who improved
because of specific treatments, development of toler-
ance, discontinuation of toxic medications, or even ad-
aptation to chronic GVHD.
In summary, in our cohort, response at 6months af-
ter enrollmentwas correlatedwith changes in symptom
burden among incident cases but not among prevalent
cases. Response at 6 months was not associated with
changes in QOL or survival outcomes in either group.
Modifications of the current response algorithm are
needed to improve correlations with clinical benefits,
such as changes in QOL and survival outcomes. Alter-
natively, validation of other more meaningful clinical
endpoints is warranted for future clinical trials of treat-
ment for patients with chronic GVHD.ACKNOWLEDGMENTS
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